Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Onyx Shifts Priorities Away From JAK Inhibitors, Puts More Emphasis on Carfilzomib

This article was originally published in The Pink Sheet Daily

Executive Summary

Onyx Pharmaceuticals opted out of a licensing agreement with Singapore's S*Bio for JAK2 inhibitors, while shifting more of its focus to proteasome inhibitor carfilzomib.

You may also be interested in...



Oncothyreon Looks To Leave Merck KGaA's Shadow With Two Cancer Candidates

While awaiting Phase III data on its partnered cancer vaccine Stimuvax, the Seattle biotech is advancing its own PI3 kinase inhibitor and follow-on vaccine projects.

Oncothyreon Looks To Leave Merck KGaA's Shadow With Two Cancer Candidates

While awaiting Phase III data on its partnered cancer vaccine Stimuvax, the Seattle biotech is advancing its own PI3 kinase inhibitor and follow-on vaccine projects.

Oncology NDAs Based On Single-Arm Studies Run Risk Of FDA Refusal To File

Oncology drug sponsors who seek FDA accelerated approval based upon single-arm studies run the risk of a “refuse-to-file” letter, a new analysis suggests.

Related Content

Topics

UsernamePublicRestriction

Register

PS072322

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel